- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01647750
Study of Optimal Replacement of Thyroxine in the Elderly (SORTED)
Study of Optimal Replacement of Thyroxine in the Elderly (SORTED) SORTED 1 - a Randomised Controlled Trial (Pilot Study), SORTED 2 - Qualitative Interviews, SORTED 3 - Retrospective Cohort
All patients with hypothyroidism are currently treated the same way, regardless of age. The investigators want to look at whether people aged 80 years or older would benefit from being treated with lower doses of levothyroxine. There are three reasons why the investigators think this could be beneficial, but this is not yet proven:
- Some older people with hypothyroidism may have few symptoms.
- Doctors look at the amount of Thyroid Stimulating Hormone (TSH) in the patient's blood to decide the dose of Thyroxine received. The standard "normal" TSH range used to determine the dose of levothyroxine is from younger people. The investigators wonder whether this is appropriate to all age ranges particularly as the investigators know that older people may normally have higher TSH values.
- If TSH levels are too low there may be a slight increased risk of problems such as brittle bones or an irregular heartbeat.
The best way to test whether older people benefit from lower doses of levothyroxine is by a large clinical trial. Before the investigators can do this, the investigators need to run a smaller clinical trial called a "pilot study" (SORTED 1) to examine whether this is practical and acceptable. The pilot study aims to recruit 50 patients with hypothyroidism aged 80 or above.
Participants will be randomly allocated to receive their routine or lower dose of levothyroxine. Follow-up will be conducted over approximately 25 weeks.
The investigators also propose a qualitative study (SORTED 2) to specifically understand patient's willingness to take part in a RCT and participant's experience of the intervention.
Finally, the investigators propose a retrospective cohort study of 400 treated hypothyroid patients aged 80 years or more registered in 2008 in Primary Care Practices with the aim of studying outcomes after 4 years. The cohort study will collect data required to inform a sample size calculation for a future full study where the primary outcome will be 4 year mortality.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Tyne and Wear
-
Gateshead, Tyne and Wear, United Kingdom, NE8 4YL
- Bensham Hospital
-
Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE1 4LP
- Clinical Research Facility
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and Females aged 80 years or older
- Diagnosed with hypothyroidism and treated with Levothyroxine for at least 6 months
- Living independently in the community
- All TSH results within the range 0.4 - 4mU/L in the 3 months before commencing the study
- Participant has provided written informed consent for participation in the study, prior to any study-specific procedures
Exclusion Criteria:
- Established dementia and therefore deemed incapable of providing informed consent.
- Other medical conditions which, inthe opinion of the Chief Investigator, would prevent them from participating in the study (for example, end stage cancer, severe chronic health conditions where the patient is housebound)
- Nursing Homes or Residential Care Home residents
- Individuals with thyroid cancer: since they require high doses of LT4 to suppress their serum TSH
- Individuals on 25 mcg dailty of LT4: dose reduction will mean that they stop thyroid replacement treatment
- Non english speaking individuals
- Participation in any other investigational trials within the last 3 months
- Participants prescribed medications that can affect thyroid function (amiodarone, lithium, carbimazole or propylthiouracil)
- Known or suspected lactose intolerance (this would have implications for the proposed over-encapsulated IMP)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Lower dose of levothyroxine
Participants may be randomised to receive a lower dose of levothyroxine (lower than their usual dose) to achieve a target TSH level of 4.1 - 8.0 mU/L
|
Participants in the lower dose arm of the study will receive a lower dose of levothyroxine than their usual dose
Participants in the standard dose of treatment will receive their usual dose of levothyroxine
|
Other: Standard dose of levothyroxine
Patients may be randomised to receive their usual dose of levothyroxine (target TSH level 0.4 - 4.0 mU/L)
|
Participants in the lower dose arm of the study will receive a lower dose of levothyroxine than their usual dose
Participants in the standard dose of treatment will receive their usual dose of levothyroxine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participant's acceptability of study design and willingness to enter study
Time Frame: Until completion of recruitment, approximately 24 months
|
Participant's acceptability of study design as measured byt he completion rate of participants in each randomised group, as well as their willingness to enter the trial (consented participant to eligible participant approached ratio)
|
Until completion of recruitment, approximately 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participant recruitment rate
Time Frame: Until completion of recruitment, approximately 24 months
|
As measured by the number of patients randomised divided by the length of the recruitment period.
The recruitment period runs from the date that recruitment opened to the date of last randomisation.
|
Until completion of recruitment, approximately 24 months
|
Time to achieve desired TSH levels
Time Frame: Until participant completion of SORTED 1 study, approximately within 24 weeks
|
To review and assess the dose titration strategy (ie reduced LT4 dose or same dose LT4) and length of time required to achieved desired TSH levels (ie number of participants in each group that reach target TSH range at both 12 and 24 weeks)
|
Until participant completion of SORTED 1 study, approximately within 24 weeks
|
Medication compliance
Time Frame: For the duration of participant involvment in the study, maximum of 25 weeks
|
Tablet count
|
For the duration of participant involvment in the study, maximum of 25 weeks
|
The acceptability of three patient completed questionnaires
Time Frame: For the duration of participant involvement in the study, maximum of 25 weeks
|
The questionnaires include the generic QoL questionnaire (EQ-5D), validated disease-specific QoL questionanaire (ThyDQol) and disease specific hypothyroid-symptom check list (ThySC).
The time taken to complete the three questionnaires will be recorded and questionnaire completion rates will be recorded and usefulnesss of questionnaires determined.
Any third-party held required in a questionnaire's completion will be recorded.
|
For the duration of participant involvement in the study, maximum of 25 weeks
|
Assessment of mobility
Time Frame: For the duration of participant involvement in this study, maximum of 25 weeks
|
Measured by the nurse administered TUG Test, and the FRAT (Falls Risk Assessment Tool)
|
For the duration of participant involvement in this study, maximum of 25 weeks
|
Change in specific cardiovascular risk factors
Time Frame: For the duration of participant involvement in the study, maximum of 25 weeks
|
Lipid profile (total cholesterol, HDL, Triglycerides), blood pressure and body weight, and serum results
|
For the duration of participant involvement in the study, maximum of 25 weeks
|
Measure of risk of falls
Time Frame: For the duration of participant involvement in the study, maximum 25 weeks
|
Measure by nurse administrated FRAT (Falls Risk Assessment Tool) test.
|
For the duration of participant involvement in the study, maximum 25 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Salman Razvi, Gateshead Health NHS Foundation Trust
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5863
- PB-PG-0610-22139 (Other Grant/Funding Number: National Institute for Health Research Research for patient Benefit)
- 2011-004425-27 (EudraCT Number)
- ISRCTN16043724 (Registry Identifier: ISRCTN)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypothyroidism
-
Kerman University of Medical SciencesCompletedPrediction Hypothyroidism Patients Using Machine Learning Algorithms | Identification of Important Symptoms of HypothyroidismIran, Islamic Republic of
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...RecruitingHypothyroidism; IrradiationItaly
-
Cooperativas Lacteas UnidasGalician South Health Research InstituteNot yet recruitingSubclinical HypothyroidismSpain
-
IBSA Institut Biochimique SACompletedHypothyroidism;PostablativeUnited States
-
Peking Union Medical College HospitalBeijing Municipal Science & Technology CommissionCompletedSubclinical HypothyroidismChina
-
University Hospital DubravaRecruitingHypothyroidism PrimaryCroatia
-
VA Office of Research and DevelopmentCentral Arkansas Veterans Healthcare SystemCompletedSubclinical HypothyroidismUnited States
-
University of Colorado, DenverCharite University, Berlin, GermanyTerminatedHypothyroidism | Postsurgical HypothyroidismUnited States
-
AbbottDimension ResearchCompletedSubclinical HypothyroidismPakistan
Clinical Trials on Levothyroxine
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do SulUnknownAging | Interaction Drug Food | Primary HypothyroidismBrazil
-
The George Washington University Biostatistics...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedPregnancy | Subclinical Hypothyroidism | HypothyroxinemiaUnited States
-
Boston Children's HospitalCompleted
-
University of California, Los AngelesTerminatedHypothyroidismUnited States
-
Walter Reed National Military Medical CenterUnknown
-
Centre Hospitalier Universitaire de NiceWithdrawnSubclinical hypothyroïdismFrance
-
GlaxoSmithKlineCompletedHypothyroidismIndia
-
Assaf-Harofeh Medical CenterCompleted
-
Nova Scotia Health AuthorityNot yet recruitingSecondary Hypothyroidism
-
Ain Shams UniversityUnknown